#AS­CO19: Am­gen grows more con­fi­dent in KRAS G12C drug with a pos­i­tive snap­shot for lung can­cer — shares spike

CHICA­GO — Am­gen came to AS­CO as the leader in the race to de­vel­op the first tar­get­ed KRAS G12C drug for can­cer. And even as crit­ics have start­ed to take a shot at the field, they’re de­ter­mined to keep the lead straight through what’s shap­ing up as a hec­tic race among a grow­ing set of ri­vals.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER